These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34831054)

  • 1. Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.
    Franco R; Rivas-Santisteban R; Navarro G; Reyes-Resina I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature.
    Sousa JB; Fresco P; Diniz C; Goncalves J
    Recent Pat Anticancer Drug Discov; 2018; 13(1):40-69. PubMed ID: 29119938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy.
    Yang H; Zhang Z; Zhao K; Zhang Y; Yin X; Zhu G; Wang Z; Yan X; Li X; He T; Wang K
    Hum Immunol; 2024 May; 85(3):110774. PubMed ID: 38521664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Structural Insight into Adenosine A
    Karati D; Mukherjee S; Roy S
    Mol Neurobiol; 2023 Oct; 60(10):5987-6000. PubMed ID: 37391647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers.
    Gorain B; Choudhury H; Yee GS; Bhattamisra SK
    Curr Pharm Des; 2019; 25(26):2828-2841. PubMed ID: 31333092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
    Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
    J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted 4-phenylthiazoles: Development of potent and selective A
    Abdelrahman A; Yerande SG; Namasivayam V; Klapschinski TA; Alnouri MW; El-Tayeb A; Müller CE
    Eur J Med Chem; 2020 Jan; 186():111879. PubMed ID: 31780082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future.
    Borah P; Deka S; Mailavaram RP; Deb PK
    Curr Pharm Des; 2019; 25(26):2792-2807. PubMed ID: 31333097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adenosine A
    Franco R; Lillo A; Navarro G; Reyes-Resina I
    Expert Opin Ther Targets; 2022 Sep; 26(9):791-800. PubMed ID: 36300278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the adenosine receptor mechanism of the tumour immune microenvironment.
    Han Y; Dong C; Hu M; Wang X; Wang G
    Front Immunol; 2024; 15():1434118. PubMed ID: 38994361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors.
    Jamwal S; Mittal A; Kumar P; Alhayani DM; Al-Aboudi A
    Curr Pharm Des; 2019; 25(26):2892-2905. PubMed ID: 31333104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Adenosine A
    Carpenter B; Lebon G
    Front Pharmacol; 2017; 8():898. PubMed ID: 29311917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
    Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
    J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
    Abbracchio MP; Cattabeni F
    Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine receptors and Huntington's disease.
    Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.
    Al-Attraqchi OHA; Attimarad M; Venugopala KN; Nair A; Al-Attraqchi NHA
    Curr Pharm Des; 2019; 25(25):2716-2740. PubMed ID: 31333093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A
    Gao ZG; Jacobson KA
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting A3 and A2A adenosine receptors in the fight against cancer.
    Merighi S; Battistello E; Giacomelli L; Varani K; Vincenzi F; Borea PA; Gessi S
    Expert Opin Ther Targets; 2019 Aug; 23(8):669-678. PubMed ID: 31189400
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.
    Deb PK; Deka S; Borah P; Abed SN; Klotz KN
    Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of adenosine A2a receptor in cancers and autoimmune diseases.
    Ye H; Zhao J; Xu X; Zhang D; Shen H; Wang S
    Immun Inflamm Dis; 2023 Apr; 11(4):e826. PubMed ID: 37102661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.